Chasing Roche, Merck unveils adjuvant lung cancer data for Keytruda

Merck & Co’s Keytruda is the undisputed market leader in immunotherapy for non-small cell lung cancer (NSCLC), but was leapfrogged by Roche’s Tecentriq in the early-stage, adjuvant treatment setting. Now, it’s hoping to fight back with new phase 3 data.